Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years af­ter then-Am­gen R&D chief Sean Harp­er tamped the last spade of dirt on the last broad­ly fo­cused CETP cho­les­terol drug — bury­ing their $300 mil­lion up­front and the few re­main­ing hopes for the class with it — the ther­a­py has been ful­ly res­ur­rect­ed. And to­day, the NewAms­ter­dam Phar­ma crew that did the Lazarus treat­ment on obice­trapib is tak­ing an­oth­er big step on the come­back trail with a €1 bil­lion-plus re­gion­al li­cens­ing deal, com­plete with close to $150 mil­lion in up­front cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER